Europe
Rexgenero, a regenerative medicine company pioneering the development of advanced cell-based therapies to treat chronic limb-threatening ischaemia, welcomes the news announced by Atelerix that it has been awarded a grant of £267,000 from Innovate UK.
Oxford Immunotec Global PLC announced that Dr. Peter Wrighton-Smith, Chief Executive Officer, and Matt McLaughlin, Chief Financial Officer, will be participating in two upcoming investor conferences.
Polyphor AG announced that it will host a Key Opinion Leader (KOL) breakfast meeting on novel approaches to the treatment of metastatic breast cancer on Friday, September 6, 2019 in New York City.
Companies from across the globe provide updates on their business and pipelines.
Some have wondered why the agency has hit back at Novartis so hard when the data in question didn’t have any effect on the eventual outcomes of the product’s effectiveness and safety.
NuCana halted enrollment of patients in the Phase III ACELERATE trial on the advice of the study’s Independent Safety and Data Monitoring Committee.
The Phase III NEPTUNE trial assessed the combination treatment as a first-line treatment in an “all-comers population,” with the primary analysis population being patients with a high tumor mutational burden.
Motif Bio plc announced that the Company will be utilising NIAID’s1 suite of preclinical services through JMI Laboratories to evaluate iclaprim against Listeria monocytogenes, a Gram-positive bacteria causing food-borne, life-threatening infections.
Forendo Pharma announces initiation of dosing in a Phase 1b clinical study in its lead endometriosis program with the aim to demonstrate Proof of Mechanism.
Knee joint injuries, such as ligament rupture, are common in athletes. As the intact joint ligaments offer a precondition for joint stability, ligament injuries are often surgically reconstructed.
PRESS RELEASES